Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval
Kyverna’s CAR-T drug greatly improved rare SPS: patients walked 46% faster, many stopped meds; FDA filing planned 2026.
/ 352 items
#XY Event-Driven Stocks↓
Merck and Eisai Phase 3 Miss Shakes Up Kidney Cancer Race – Analysts Split on Arcus
Merck’s new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for Arcus and its drug.
Ionis’ Zilganersen Stabilizes Walking and Motor Skills in Alexander Disease Study
Ionis drug zilganersen showed promise for rare brain disease (Alexander disease), improving symptoms; FDA decision due Sept 2026.
BBOT Scores FDA Fast Track for BBO-11818: A New Targeted Therapy for KRAS-Mutant Pancreatic Cancer
BBOT receives U.S. FDA Fast Track Designation for BBO-11818, its pan-KRAS inhibitor for advanced KRAS-mutant pancreatic cancer. Phase 1 data expected H2 2026.
Arcus Biosciences Stops Phase 3 STAR-121 Lung Cancer Trial and Updates Gilead Partnership
Arcus stops a lung cancer trial early after poor outlook, ends a partner study, and gains more control as Gilead scales back the deal.
New Drug Shows Stronger Hair Regrowth After 1 Year in Severe Alopecia Areata
Nektar drug showed promising hair regrowth in severe alopecia areata after 52 weeks, with good safety and twice-monthly shots.